Italy· 047417047
TAKHZYRO*1 siringa preriemp SC 300 mg 2 ml
A lanadelumab product containing lanadelumab, registered in Italy by TAKEDA PHARM.INT.AG IR.BRANCH, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Lanadelumab is registered in 15 of 19 countries.
Countries holding a registration under ATC B06AC05 (lanadelumab), each read from that country’s own register.
- This record: Italy
- 10 of them publish a price we can compare per daily dose
Lanadelumab · ATC B06AC05
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lanadelumab costs, country by country.
Normalised to the WHO defined daily dose (21.4 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lanadelumab · price per daily dose (21.4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$857.11
The record
At a glance
- Active substance
- Lanadelumab
- Manufacturer
- TAKEDA PHARM.INT.AG IR.BRANCH
- Country
- Italy (IT)
- ATC code
- B06AC05
- ATC class
- Lanadelumab
- Defined daily dose
- 21.4 mg, P
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic047417047TAKHZYRO*1 siringa preriemp SC 300 mg 2 mlEUR 23379.57
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lanadelumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTAKHZYROTakeda Pharmaceuticals International AG Ireland Branch, Dublin
- United StatesTAKHZYROTakeda Pharmaceuticals America, Inc.
- FinlandTakhzyroOrifarm Oy
- BelgiumTakhzyro 150 mgTakeda Pharmaceuticals International Ireland Branch
- United KingdomTakhzyro 150mg/1ml solution for injection pre-filled syringesTakeda UK Ltd
- IcelandTakhzyroTakeda Pharmaceuticals International AG Ireland Branch
- NetherlandsTAKHZYRO 150 mg oplossing voor injectie in voorgevulde spuitTakeda Pharmaceuticals International AG Ireland Branch
- SwedenTAKHZYRO 150 mg Injektionsvätska, lösning i förfylld sprutaTakeda Pharmaceuticals International AG Ireland Branch
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Takhzyro
- Liechtenstein · Takhzyro
- Norway · Takhzyro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e6be783a-98ee-4e65-94fe-417af2281fef GET /v1/drugs/e6be783a-98ee-4e65-94fe-417af2281fef?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 23379.57,
"source": "aifa",
"currency": "EUR",
"strength": "LANADELUMAB 300MG 2ML 1 UNITA' USO PARENTERALE",
"substance": "Lanadelumab",
"equivalence_group": "LDR",
"transparency_flag": null
}See everything about lanadelumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.